Indication

RET-mutant medullary thyroid cancer

RET-mutant medullary thyroid cancer is a rare neuroendocrine malignancy of the endocrine system arising from the calcitonin-secreting parafollicular C cells of the thyroid gland. Read more about RET-mutant medullary thyroid cancer

0 drugs 0 manufacturers

Advertisement

Drugs that treat it

Common RET-mutant medullary thyroid cancer therapies.

0 drugs

No drugs are available

This indication does not currently contain public drugs.

Filter & compare in the drug finder →Opens the drug finder with RET-mutant medullary thyroid cancer preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About RET-mutant medullary thyroid cancer.

RET-mutant medullary thyroid cancer is a rare neuroendocrine malignancy of the endocrine system arising from the calcitonin-secreting parafollicular C cells of the thyroid gland.

It is defined by activating mutations in the *RET* proto-oncogene, which encode a constitutively active receptor tyrosine kinase that drives unregulated cellular proliferation and survival.

These oncogenic alterations can occur as inherited germline mutations—often associated with multiple endocrine neoplasia type 2 (MEN2) syndromes—or as acquired somatic mutations in sporadic tumors.

Clinically, it frequently presents as a thyroid nodule accompanied by elevated serum calcitonin and carcinoembryonic antigen (CEA) levels, and it carries a high propensity for early lymph node involvement and distant metastatic spread.

Personalize your experience

Follow RET-mutant medullary thyroid cancer and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it